Background. STEC and NTS are leading causes of foodborne infections in the US. Monitoring resistance in these pathogens is essential to understand the distribution of resistance profiles and because of the high likelihood of horizontal transfer of resistance genes to other pathogens. Data involving resistance in clinical STEC and NTS isolates from Michigan is lacking.
Background. Ceftolozane-tazobactam (C-T) is a combination of a novel antipseudomonal cephalosporin and a well-described β-lactamase inhibitor. C-T was approved by the United States (US) Food and Drug Administration in 2014 for complicated urinary tract infections, including acute pyelonephritis and complicated intra-abdominal infections. C-T is currently in clinical trials for the treatment of hospital-acquired pneumonia. The Program to Assess Ceftolozane-Tazobactam Susceptibility (PACTS) monitors C-T resistance to gram-negative (GN) isolates worldwide. This study compares the activities of C-T and comparators against GN isolates from ICU patients and non-ICU patients.
Methods. A total of 3,100 GN ICU isolates and 3,271 isolates from non-ICU patients were collected from 30 US hospitals in 2012-2016. Isolates were tested for susceptibility (S) to C-T and comparators by CLSI broth microdilution methodology in a central monitoring laboratory. Other antibiotics tested included amikacin (AMK), cefepime (FEP), ceftazidime (CAZ), colistin (COL), meropenem (MER), and piperacillin-tazobactam (TZP). CLSI (2017) interpretive criteria were used for all except COL with Enterobacteriaceae (ENT), for which EUCAST (2017) criteria were used.
Results. The most common ENT species from ICU and non-ICU patients were similar. The 3 most common ENT for ICU and non-ICU isolates were Klebsiella pneumoniae, 24.1% and 25.8%; Escherichia coli, 19.4% and 18.2%; and Serratia marcescens, 14.7% and 14.3%, respectively. The most common non-enteric species was Pseudomonas aeruginosa (PSA) for ICU and non-ICU (72.7% and 78.2%). ICU ENT isolates generally had a lower %S than non-ICU (Table) . ENT showed more variability than PSA for %S between ICU and non-ICU.
Conclusion. For ENT overall, MER and AMK were the most active, followed by C-T. Comparing ICU and non-ICU, MER and C-T were slightly more active vs. non-ICU ENT, while AMK %S was similar for both. For PSA, COL was the most active; C-T and AMK were similar. Activities between ICU and non-ICU isolates were similar for C-T and COL while AMK was more active vs. ICU isolates, and MER was more active vs. non-ICU. C-T showed potent activity against ICU and non-ICU isolates for ENT and PSA. Background. Cefiderocol (S-649266) is a novel siderophore cephalosporin active against a wide variety of Gram-negative bacteria, not only Enterobacteriaceae but also non-fermenting bacteria such as Pseudomonas aeruginosa and Acinetobacter spp., including carbapenem-resistant strains. This potent activity is due to its efficient penetration through the outer membrane via active iron transporter systems and its high stability to both serine-and metallo-carbapenemases.This study evaluated the in vitro activity of cefiderocol and comparator agents against carbapenem-resistant clinical isolates collected from urinary track source in 2014-2016 from global countries.
Methods /Methods. Carbapenem-resistant Enterobacteriaceae (CRE) and multidrug-resistant (MDR) non-fermenters (defined as resistant to imipenem, ciprofloxacin and amikacin) were collected globally from 2014 to 2016 by IHMA Inc. A total of 226 Enterobacteriaceae, 44 Acinetobacter baumannii, 45 P. aeruginosa, 7 Stenotrophomonas maltophilia and 1 Burkholderia cepacia isolated from a urinary track source were tested. MICs were determined for cefiderocol, cefepime (FEP), ceftazidime-avibactam (CZA), ceftolozane-tazobactam (C/T), ciprofloxacin (CIP), colistin (CST), and meropenem (MEM) by broth microdilution and interpreted according to CLSI 2016 guidelines. As recommended by CLSI, cefiderocol was tested in iron-depleted cation-adjusted Mueller Hinton broth. Quality control testing was performed on each day of testing by using E. coli ATCC25922 and P. aeruginosa ATCC27853.
Results. MIC 90 of cefiderocol against carbapenem-resistant Enterobacteriaceae, MDR P. aeruginosa, MDR A. baumannii, and S. maltophilia were 4 µg/mL or less. However, MEM, C/T and CZA had MIC 90 s of >64µg/mL. Cefiderocol demonstrated potent in vitro activity against carbapenem-resistant Enterobacteriaceae, A. baumannii, and P. aeruginosa isolates collected from a UTI source. At 4 µg/mL or less, cefiderocol inhibited the growth of 95.8% of the isolates.
Conclusion. These results strongly indicated that cefiderocol is a promising candidate for the treatment of the serious infections caused by cUTI isolated Gramnegative bacteria including carbapenem-resistant strains. 
